A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury
Phase 1
10
about 12 years
18–65
2 sites in CA
What this study is about
This trial is testing a new device to deliver LCTOPC1, a cell therapy, to people with spinal cord injuries. The goal is to see if this delivery method is safe.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive OPC1
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Frequency and Severity of Adverse Events Related to the Delivery Device or Injection Procedure Through 30 Days
Secondary: Frequency and Severity of Adverse Events Related to LCTOPC1 and/or the Concomitant Immunosuppression Through 90 Days, Incidence of MRI Findings Indicative of Deterioration or Safety-Related Changes at 90 Days
Neurology